-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-executive-summary-2023-update.pdf
January 01, 2023 - In patients with chronic (mainly neuropathic) pain
with short-term treatment (4 weeks to <6 months): … : Benefits of cannabinoids for chronic pain compared with placebo
in the short term (4 weeks to <6 months … Question 2: Harms of cannabinoids for chronic pain compared with placebo
in the short term (4 weeks to <6 months
-
effectivehealthcare.ahrq.gov/sites/default/files/cer-243-prehospital-airway-management-evidence-summary_0.pdf
June 01, 2021 - Comparative Effectiveness Reiew 243_Prehospital Airway Management: A Systematic Review
Comparative Effectiveness Review
Number 243
Prehospital Airway Management:
A Systematic Review
Evidence Summary
Main Points
• Four Key Questions addressed the comparative benefits and harms across …
-
effectivehealthcare.ahrq.gov/sites/default/files/antipsychotics-children-update_executive.pdf
January 01, 2018 - Long term: ≥6 months-<12 months; 12 months+
Setting Any setting
Design Clinical trials (RCTs and … We
accounted for duration of response, that is, short- (< 6 months) and long-term (≥ 6 months - < 12 … months; ≥ 12 months). … One hundred
and one (75%) studies reported on followup durations
of < 6 months, 10 reported on both … Most studies had
treatment durations between 4 and 12 weeks; nine studies
were 6 months or longer.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/epilepsy-medicine_disposition-comments.pdf
March 01, 2012 - responses to the comments are posted for
public viewing on the EHC Program Web site approximately 3 months … and for topiramate versus
carbamazepine at 12 months. … We have made the following change:
The risk of seizure freedom at 12 or 24 months
was significantly … agents versus carbamazepine, therefore patients
were more likely to be seizure free at 12 or 24
months … ADAS-COG: LEV
produced clinical improvement over 12 months while there was a
worsening with PHB and
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/epc-evidence-reviews-federal-agencies.pdf
July 01, 2020 - Federal agencies should estimate about 5 months from agreement on the scope of work to the start of the
-
effectivehealthcare.ahrq.gov/sites/default/files/data-points_2_diabetic-foot-ulcers_data_02-2011.xlsx
January 01, 2011 - DFU Incidence
Annual Incidence of Foot Ulcer Among Diabetic Medicare Parts A and B Fee-for-Service Beneficiaries, 2006-2008
By Age Category, Gender, and Race, and Broken Down by Diagnosis of Peripheral Artery Disease (PAD)
(Algorithm 3: 12-month period of continuous enrollment and continuous FFS enrollment throug…
-
effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1512.pdf
December 01, 2015 - depending on expert comments received on interventions issued for
comment during the preceding 6 months … This test indicates the
patient’s average blood sugar level for the previous 2 or 3 months, and an … ITCA 650
reportedly remains stable at body temperature for delivery up to 12 months, based on data … “Discontinuations for nausea were in the low single
digits over the full 12 months of treatment. … The longest implant prior to Iluvien was a dexamethasone implant that lasted about 4
months.
-
effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1506.pdf
June 01, 2015 - depending on expert comments received on interventions issued for
comment during the preceding 6 months … The Reshape Duo is designed to
be kept in the stomach for 6 months and then removed, using an endoscopic … intragastric balloons.4
The Reshape Duo is designed to be kept in the stomach for no longer than 6 months … However, these are likely to remit
over time with weight regain once the device is removed at 6 months … , then at least every 3 months in all patients prescribed weight-loss medications.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/tympanostomy-tubes-disposition.pdf
May 05, 2017 - the authors’ responses to the comments are posted for
public viewing on the Web site approximately 3 months … compared to
watchful waiting, but there
is no benefit at 12 to 24
months.” … In this case "late" has been
specifically defined as 12-24 months an has been
retained in preference … delayed TT
In both ES and Full report, we removed duplicated
discussion and added "(mean age 3 months … )" and
"mean age 40.8 months or not at all in two
subjects)" in summary of Hubbard, 1985.
-
effectivehealthcare.ahrq.gov/sites/default/files/tympanostomy-tubes-disposition.pdf
May 05, 2017 - the authors’ responses to the comments are posted for
public viewing on the Web site approximately 3 months … compared to
watchful waiting, but there
is no benefit at 12 to 24
months.” … In this case "late" has been
specifically defined as 12-24 months an has been
retained in preference … delayed TT
In both ES and Full report, we removed duplicated
discussion and added "(mean age 3 months … )" and
"mean age 40.8 months or not at all in two
subjects)" in summary of Hubbard, 1985.
-
effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/white-paper-library-afib.pdf
November 15, 2018 - disability measurement should be performed using the
modified Rankin Scale (mRS) at discharge and 6 months … disability measurement should be performed using the modified
Rankin Scale (mRS) at discharge and 6 months … early recurrences of AF/AFL/AT are to be expected following AF ablation,
recurrent AF/AFL/AT within 3 months
-
effectivehealthcare.ahrq.gov/sites/default/files/celiac-disease_disposition-comments.pdf
January 28, 2016 - responses to the comments are posted for
public viewing on the EHC Program Web site approximately 3 months … The
discussion of children under 24 months versus
older children does not include the recognized
phenomenon … adults, but it is widely recognized
that TTG is relatively insensitive in children
younger than 24 months … However, only one study comparing
accuracy between children under 24 months old and
older children … reported higher sensitivity and specificity (.96 and .98
respectively) for children under age 24 months
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/prostatic-hyperplasia-medications_research-protocol.pdf
April 21, 2015 - serious medication side effects
Timing
Short term outcomes - treatment duration between 1 and 6 months … Intermediate outcomes - treatment duration of at least 6 months and less than 1 year
Long term outcomes … studies (medication for treatment of
LUTS/BPH, sample size at least 100; study duration at least 6 months … • Sustained efficacy/comparative effectiveness: over 6 months
Publication type Published in peer … The disposition of comments for systematic
reviews and technical briefs will be published three months
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/bariatric-surgery-trends_research.pdf
November 01, 2012 - Medicare eligibility, 2006-2009*
90
92
94
96
98
100
0 12 24 36 48
%
su
rv
iv
in
g
Months … type of operation, 2006-2009*
90
92
94
96
98
100
0 12 24 36 48
%
su
rv
iv
in
g
Months … 96
97
98
99
100
0 12 24 36 48
%
re
m
ai
ni
ng
en
ro
lle
d
in
M
ed
ica
re
Months … 96
97
98
99
100
0 12 24 36 48
%
re
m
ai
ni
ng
en
ro
lle
d
in
M
ed
ica
re
Months
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/renal-update_research-protocol.pdf
January 15, 2015 - compared to renal
artery angioplasty with stent placement on long-term clinical outcomes (at least 6
months … [Type text] [Type text] [Type text]
• ≥6 months … (except adverse events) (≥12 months of primary interest)
Setting
• Any
• Any language, as feasible … The disposition of comments for systematic
reviews and technical briefs will be published three months
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/c-diff-infections_research-protocol.pdf
May 24, 2010 - pathogenesis of CDAD is complex and incompletely understood, and
on-set may occur as late as several months … Antibiotic and non-standard treatments: variable, generally ranging from 4 weeks to several
months … Prevention: variable, generally from 6 months up to 2 years
• Settings:
Health care facilities … the peer review comments are documented and will, for CERs and Technical briefs, be
published three months
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/antipsychotic-medicine-cardiovascular-elderly_research.pdf
February 01, 2009 - subjects were required to have utilized >1 medical service and >1
prescription, both within the 6 months … prior to the index date as well as in the >6 months before
the index date. … opportunistic infection.28
Other Covariates
We defined the following patient characteristics in the 6 months … include the possibility that patients who did not fill
antipsychotic medications in the prior six months
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/alcohol-misuse-drug-therapy_disposition-comments.pdf
May 13, 2014 - responses to the comments are posted for
public viewing on the EHC Program Web site approximately 3 months … The trial found no difference between
groups for the primary outcome of abstinence over
12 months.” … Also
several of the acamprosate studies were conducted for 6 to 12 months. … Conclusion
Page 92, lines 36-41: I question the statement that treatment periods of less
than 6 months … Using the intent
to treat the effect disappeared after three months.
-
effectivehealthcare.ahrq.gov/sites/default/files/pregnancy-horizon-scan-high-impact-1412.pdf
December 01, 2014 - depending on expert comments received on interventions issued for
comment during the preceding 6 months … More recently (in the past 12–15 months), even
fewer topics have met criteria for tracking because
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/medication-therapy-management-1_research.pdf
July 01, 2012 - • 3 or more providers seen within 12 months. … Have you been to the emergency room in the last 3 months? … Have you been admitted to the hospital in the last 3 months? … Have you visited your doctor in the last 3 months? … How many times have you visited your doctor in the last 3 months?